Illumina, Inc. (NASDAQ:ILMN) Expected to Post Earnings of $0.87 Per Share

Equities analysts forecast that Illumina, Inc. (NASDAQ:ILMNGet Rating) will announce earnings of $0.87 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Illumina’s earnings. The highest EPS estimate is $0.98 and the lowest is $0.75. Illumina posted earnings of $1.89 per share in the same quarter last year, which would indicate a negative year over year growth rate of 54%. The business is scheduled to report its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Illumina will report full year earnings of $4.14 per share for the current year, with EPS estimates ranging from $4.12 to $4.19. For the next year, analysts expect that the business will report earnings of $5.79 per share, with EPS estimates ranging from $4.75 to $8.45. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Illumina.

Illumina (NASDAQ:ILMNGet Rating) last released its earnings results on Thursday, February 10th. The life sciences company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.50 by $0.25. Illumina had a net margin of 16.82% and a return on equity of 11.35%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the business earned $1.22 earnings per share. The business’s quarterly revenue was up 25.2% on a year-over-year basis.

ILMN has been the subject of several recent analyst reports. Bank of America raised shares of Illumina from an “underperform” rating to a “neutral” rating and set a $390.00 price objective for the company in a report on Friday, January 7th. Piper Sandler raised their price objective on shares of Illumina from $450.00 to $460.00 and gave the company an “overweight” rating in a research report on Tuesday, February 15th. Robert W. Baird reduced their target price on shares of Illumina from $437.00 to $380.00 in a research note on Friday, February 11th. Zacks Investment Research raised shares of Illumina from a “strong sell” rating to a “hold” rating and set a $399.00 price objective on the stock in a research note on Tuesday, January 4th. Finally, Stifel Nicolaus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $480.00 price objective on the stock in a research note on Tuesday, January 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $421.91.

Shares of ILMN traded down $6.86 during mid-day trading on Friday, hitting $336.49. 582,899 shares of the company’s stock were exchanged, compared to its average volume of 744,962. The company has a quick ratio of 2.09, a current ratio of 2.48 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average of $337.25 and a two-hundred day moving average of $367.91. The stock has a market cap of $52.85 billion, a price-to-earnings ratio of 66.63, a P/E/G ratio of 2.60 and a beta of 0.94. Illumina has a twelve month low of $302.79 and a twelve month high of $526.00.

In related news, SVP Phillip G. Febbo sold 1,988 shares of Illumina stock in a transaction dated Wednesday, April 6th. The stock was sold at an average price of $360.01, for a total value of $715,699.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Aimee L. Hoyt sold 2,474 shares of the firm’s stock in a transaction dated Tuesday, April 12th. The stock was sold at an average price of $350.51, for a total value of $867,161.74. Following the completion of the transaction, the senior vice president now owns 5,342 shares of the company’s stock, valued at approximately $1,872,424.42. The disclosure for this sale can be found here. Insiders sold a total of 4,830 shares of company stock valued at $1,709,023 over the last three months. 0.23% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. increased its stake in Illumina by 321.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,028 shares of the life sciences company’s stock worth $823,000 after purchasing an additional 1,547 shares during the period. JJJ Advisors Inc. boosted its position in shares of Illumina by 25.8% during the third quarter. JJJ Advisors Inc. now owns 151 shares of the life sciences company’s stock valued at $61,000 after purchasing an additional 31 shares in the last quarter. Avantax Advisory Services Inc. boosted its holdings in Illumina by 22.1% in the third quarter. Avantax Advisory Services Inc. now owns 1,149 shares of the life sciences company’s stock worth $466,000 after acquiring an additional 208 shares in the last quarter. Kestra Private Wealth Services LLC boosted its holdings in Illumina by 9.5% in the third quarter. Kestra Private Wealth Services LLC now owns 1,986 shares of the life sciences company’s stock worth $806,000 after acquiring an additional 173 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in Illumina by 10.4% in the third quarter. Park Avenue Securities LLC now owns 3,471 shares of the life sciences company’s stock worth $1,408,000 after acquiring an additional 326 shares in the last quarter. Institutional investors own 85.41% of the company’s stock.

About Illumina (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Recommended Stories

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.